



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Letter to the Editor

Humoral SARS-COV-2 IgG decay within 6 months in COVID-19 healthy vaccinees: The need for a booster vaccine dose?



ARTICLE INFO

Keywords

COVID-19

Vaccination

IgG antibody

Humoral immunity

T_{1/2}

The most effective approach to fight COVID-19 infection is prevention by targeted vaccines that prime the immune system prior to a first encounter with the virus. The BNT162b2 messenger RNA (mRNA) vaccine encoding the SARS-CoV-2 full length spike generates antibodies that prevent the entry of the virus into cells by blocking either ACE2-RBD binding interactions or spike-mediated membrane fusion [1]. The vaccine proved efficient in a large multinational trial, including 21,720 subjects vaccinated with BNT162b2. The study demonstrated 95% efficacy in preventing COVID-19 disease [2]. As the process of vaccination against COVID-19 is currently spreading all over the world, it is of importance to assess the longevity of the humoral immune response to the vaccination. A high percentage of protective antibody responses was reported 7 days after full vaccination with BNT162b2 [3]. In a very recent study anti-RBD IgG was detected in 100% of fully vaccinated individuals at days 33-55 for both the Moderna and Pfizer cohorts [4]. To better understand the longevity of the humoral response, we conducted a prospective longitudinal study among a cohort of healthy vaccinees up to eight months from the second vaccine dose. The study was approved by Sheba Medical Center Institutional Review Board (approval number Sheba.SMC-8182-21), and all participants signed written informed consent. All participants had no prior infection with SARS-CoV-2, and no evidence of infection during the study. Subjects received two PfizerBNT162b2 vaccine doses, 21 days apart, delivered in the deltoid muscle. SARS-CoV-2 anti-spike IgG levels were measured at least 28 days following the second vaccine dose at two or more time points and spike IgG titer average $t_{1/2}$ was calculated using linear regression from log₂-transformed data for each pair, according to the following equation $t_{1/2} = \text{Elapsed time} \cdot \log_2 / \log[\text{Beginning amount} / \text{Ending amount}]$. Immunoassay for the detection of SARS-CoV-2 IgG antibodies was performed using anti-SARS-CoV-2 QuantiVac ELISA IgG (Euroimmun, Lubeck, Germany) based on the S1 domain of the spike protein. Cut-off for positive IgG level was determined as >35.2 binding antibody units (BAU)/ml. The test has a sensitivity of 93.2% and a specificity of 100%. Correlation with neutralization tests was reported to be 98.2% (<https://www.euroimmun.de/en/>).

Thirty-nine vaccinated subjects, 9 males, 30 females, mean±SD age 54.3±15.24 years, median 57.8 years, range 25.9-89.0 years, followed

for median 4.3 months, range 1.0 - 8.3 months after the second vaccine dose, were included in the study. The time interval between the first and second paired IgG tests was median 83 days, (25 IQR-75 IQR) 64-98 days, range 20 to 142 days. Spike IgG titers (BAU/ml) were heterogeneous among subjects, median 921, (25 IQR-75 IQR) 505-1376, range 19.2-3840.0). The decline from the first to the second time point in spike IgG titers (BAU/ml) was median 617.6, (25 IQR-75 IQR) 300.8-960.0, range 12.8-2764.8). Fig. 1 demonstrates the durability of paired assessments of circulating antibody titers based on data ≥28 days post the second vaccine dose. The antibody responses decay kinetics showed median $t_{1/2}$ of 45 days, (25 IQR-75 IQR) 38.2-62.3 days. SARS-CoV-2 IgG titers inversely correlated with age ($r = -0.323$), and SARS-CoV-2 IgG decline corrected for baseline level correlated with age ≥60 years ($r = 0.277$), while in younger subjects <60 years an inverse correlation was observed ($r = -0.502$). No significant differences were observed in the decay kinetics in relation with gender. Our findings demonstrate that anti-S1 IgG levels determined across 1 to 8 months after full vaccination, waned with an estimated half-life of 45 days. Age was associated with lower post-vaccination anti-S1 IgG titers and with accelerated IgG decrease over time. Moreover, we calculated that within 225 days ($5 \cdot t_{1/2}$), IgG will decrease below detection level, raising the need for reconsidering the current mRNA vaccine regimens. In comparison, seasonal coronavirus protective immunity in convalescents was reported to be similarly short-lasting up to one year [5]. However, for SARS-CoV and MERS, IgG antibodies remained detectable in 100% and 74.2% of subjects respectively, for 1-3 years post-infection [6]. Our group recently reported that 85% of convalescent COVID-19 subjects had a protective IgG level that prevailed over a period of up to 9 months post-infection, regardless of age or gender [7].

The question of long-lasting and protective vaccine immunity against SARS-CoV-2 is of major importance as the decay suggests the need for an additional booster. A decrease in IgG levels impairs the equilibrium between COVID-19 viral load during exposure and humoral protection. The induction and decay of antigen-specific IgG response to COVID-19 mRNA vaccine are consistent with the known serum T_{1/2} of various IgG subclasses immunoglobulin [8]. Among fully vaccinated health care workers, the occurrence of SARS-CoV-2 infection correlated with lower

<https://doi.org/10.1016/j.ejim.2021.10.027>

Received 11 October 2021; Accepted 18 October 2021

Available online 27 October 2021

0953-6205/© 2021 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.




Fig. 1. Paired circulating antibodies to SARS-CoV-2 over time in healthy vaccinated subjects. Longitudinal spike IgG ($n=39$, BAU/ml), median $t_{1/2}=45$ days; 25-75 IQR 38.2-62.3 days. The red line indicates the cutoff. Subjects aged >60 years are depicted in red, subjects aged ≤ 60 years in light blue.

neutralizing antibody titers during the peri-infection period [9]. Older vaccinees, aged ≥ 60 years, demonstrated a more profound decrease in IgG levels over time and are therefore at increased risk for infection with COVID-19 and COVID-19 variants. The Israeli healthcare authorities in accordance recently launched the third vaccination booster in people older than 60 years of age.

CRedit authorship contribution statement

Anat Achiron: Data curation, Funding acquisition, Writing – original draft, Funding acquisition, Writing – review & editing. **Mathilda Mandel:** Conceptualization, Data curation, Writing – original draft, Writing – review & editing. **Sapir Dreyer-Alster:** Visualization, Software, Data curation, Writing – review & editing. **Gil Harari:** Formal analysis, Data curation, Writing – review & editing. **Michael Gurevich:** Data curation, Supervision, Writing – review & editing.

Declaration of Competing Interest

Anat Achiron, MD, PhD - no conflicts of interest. Mathilda Mandel, MD, MHA - no conflicts of interest. Sapir Dreyer-Alster, BSc - no conflicts of interest. Gil Harari, PhD - no conflicts of interest. Michael Gurevich - no conflicts of interest.

Funding/Support

This work was funded by research grants from the Sheba Medical Center (GN. 04027-10/1001493), and the Laura Schwarz-Kipp Research Fund for Autoimmune Diseases (GN. 0601253231), Sackler School of Medicine, Tel-Aviv University, Israel.

References

- [1] Vogel AB, Kanevsky I, Che Y, et al. BNT162b vaccines are immunogenic and protect non-human primates against SARS-CoV-2. *bioRxiv* 2020;12:421008.
- [2] Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *N Engl J Med* 2020;383:2603–15.
- [3] Wei J, Stoesser N, Matthews PC, et al. COVID-19 Infection Survey team. Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom. *Nat Microbiol* 2021;21:1–10. Jul.
- [4] Bliden KP, Liu T, Sreedhar D, et al. Evolution of Anti-SARS-CoV-2 IgG Antibody and IgG Avidity Post Pfizer and Moderna mRNA Vaccinations. *medRxiv* 2021;06(28): 21259338.
- [5] Edridge AWD, Kaczorowska J, Hoste ACR, et al. Seasonal coronavirus protective immunity is short-lasting. *Nat Med* 2020;26:1691–3.
- [6] Huang AT, Garcia-Carreras B, Hitchings MDT, et al. A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity. *Nat Commun* 2020;11:4704.
- [7] Achiron A, Gurevich M, Falb R, Dreyer-Alster S, Sonis P, Mandel M. SARS-CoV-2 antibody dynamics and B-cell memory response over time in COVID-19 convalescent subjects. *Clin Microbiol Infect* 2021;S1198-743X(21). 00229-9.
- [8] Mankarious S, Lee M, Fischer S, et al. The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin. *J Lab Clin Med* 1988;112:634–40.
- [9] Bergwerk M, Gonen T, Lustig Y, et al. Covid-19 breakthrough infections in vaccinated health care workers. *N Engl J Med* 2021. Jul 28.

Anat Achiron^{a,*}, Mathilda Mandel^a, Sapir Dreyer-Alster^a, Gil Harari^b,
Michael Gurevich^c

^a Multiple Sclerosis Center, Sheba Medical Center Tel-Hashomer, Israel and
Laura Schwarz-Kipp Research of Autoimmune Diseases, Sackler School of
Medicine Tel-Aviv University, Israel.

^b School of Public Health, University of Haifa, Israel

^c Neuroimmunology Laboratory, Multiple Sclerosis Center, Sheba Medical
Center, Ramat-Gann, Israel

* Corresponding author at: Laura Schwarz-Kipp Research of
Autoimmune Diseases, Sackler School, of Medicine Tel-Aviv University,
Neuroimmunology Laboratory, Multiple Sclerosis Center, Sheba
Medical Center, Israel.

E-mail address: anat.achiron@sheba.health.gov.il (A. Achiron).